Curis (NASDAQ:CRIS) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Curis (NASDAQ:CRIS) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $26.00 target price on the biotechnology company’s stock.

Several other research analysts also recently issued reports on the stock. Cantor Fitzgerald reissued an overweight rating on shares of Curis in a research report on Wednesday, May 15th. Truist Financial reaffirmed a buy rating and issued a $26.00 target price on shares of Curis in a report on Wednesday, May 15th.

Curis Stock Performance

Shares of Curis stock opened at $5.00 on Thursday. Curis has a 1 year low of $3.80 and a 1 year high of $17.49. The company has a market capitalization of $29.45 million, a P/E ratio of -0.58 and a beta of 3.35. The company’s fifty day moving average is $7.58 and its two-hundred day moving average is $10.52.

Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.36). Curis had a negative return on equity of 243.03% and a negative net margin of 468.18%. The business had revenue of $2.55 million for the quarter, compared to analysts’ expectations of $2.20 million. During the same period in the previous year, the business posted ($2.40) earnings per share. As a group, equities analysts expect that Curis will post -5.39 earnings per share for the current year.

Institutional Trading of Curis

Institutional investors have recently added to or reduced their stakes in the stock. a16z Perennial Management L.P. acquired a new stake in shares of Curis during the fourth quarter worth $85,000. Franklin Street Advisors Inc. NC acquired a new stake in shares of Curis during the first quarter worth $219,000. Focused Wealth Management Inc raised its holdings in shares of Curis by 79.2% during the first quarter. Focused Wealth Management Inc now owns 33,158 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 14,656 shares during the period. CM Management LLC raised its holdings in shares of Curis by 380.0% during the first quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after purchasing an additional 95,000 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Curis by 4.8% during the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after acquiring an additional 10,097 shares during the last quarter. 29.97% of the stock is owned by institutional investors and hedge funds.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.